Clinical trial
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
NCT00180128 · Technische Universität Dresden, Other · Unknown status
Key facts
| NCT number | NCT00180128 |
|---|---|
| Title | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia |
| Official title | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) |
| Lead sponsor | Technische Universität Dresden, Other |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Leukemia, Promyelocytic, Acute |
| Intervention type | Drug |
| Interventions | all-trans retinoid acid, idarubicin, mitoxantrone, daunorubicin, cytarabine |
| Enrollment | 80 |
| Start date | Jan 1, 2000 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Sep 16, 2005 |
| Last update posted | Jul 11, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: